An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice

Particle and Fibre Toxicology

Xiu-Min Han¹  Jian-Hai Yin²  Qi Zheng²  Bin Jiang²  Chao-Wei Zhang²  Wen Lei¹  Hao-Bing Zhang²  Cong-Shan Liu² 

[1] Qinghai Institute for Endemic Disease Prevention and Control, Xining 811602, Qinghai, China;National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Key Laboratory of Parasite and Vector Biology, MOH, WHO Collaborating Centre for Malaria, Schistosomiasis and Filariasis, Shanghai 200025, China

关键词: Liver function test;    Histopathology examination;    Pharmacokinetics;    Treatment efficacy;    Cystic echinococcosis;    Mebendazole oily suspension;   

Others  :  1148548
DOI  :  10.1186/s13071-014-0589-0

 received in 2014-05-29, accepted in 2014-12-04,  发布年份 2014

【 摘 要 】

Background

Cystic echinococcosis is a serious zoonotic infection worldwide caused by metacestodes of Echinococcus gruanulosus. Mebendazole and albendazole are the only two drugs used in the treatment of this disease with cure rates only about 30% due to the poor oral absorption. Thus an alternative treatment for this disease is needed.

Methods

A mebendazole oily suspension (MBZ-OS) was prepared and orally administrated to mice infected with echinococcus cysts for 8 months at 12.5 mg/kg and 25 mg/kg for 14 consecutive days. Mebendazole suspended in 1% tragacanth (MBZ-1% tragacanth) served as treated control. In addition, liver and serum samples were collected from these treated mice (25 mg/kg) for histopathology examination and liver function test. For pharmacokinetic analysis, plasma, parasite (cyst wall and cyst fluid) and tissue samples were collected at 0.25, 0.5, 1, 2, 4, 8, 16 and 24 h after orally administrating MBZ-OS and MBZ-1% tragacanth to E. granulosus-infected mice at 25 mg/kg. These samples were then processed and quantitatively analyzed by HPLC.

Results

The administration of MBZ-OS resulted in a treatment efficacy with the cyst weight reductions higher than 80%, significantly better than the corresponding MBZ-1% tragacanth groups. The better treatment efficacy of MBZ-OS was related to the higher drug concentration in plasma, parasites and tissues. It was also shown that the injury of the liver was not significantly altered by taking MBZ-OS compared to the untreated control.

Conclusion

These findings demonstrate that MBZ-OS is a promising new formulation of MBZ for treatment of hydatid diseases without showing significantly liver toxicity.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Eckert J, Deplazes P: Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin Microbiol Rev 2004, 17:107-135.
• [2]Eckert J, Conraths FJ, Tackmann K: Echinococcosis: an emerging or re-emerging zoonosis? Int J Parasitol 2000, 30:1283-1294.
• [3]Jiang CP: Preliminary clinical obserations on mebendazole and traditional Chinese medicine treatment in 57 cases with echinococcosis. Chin J Parasitol Parasit Dis 1996, 4:209-210.
• [4]Wang LY, Wu WP, Zhu XH: The endemic status of hydatidosis in China from 2004 to 2008. Chin J Zoonoses 2010, 26:699-702.
• [5]Yang YR, Clements AC, Gray DJ, Atkinson JA, Williams GM, Barnes TS, McManus DP: Impact of anthropogenic and natural environmental changes on Echinococcus transmission in Ningxia Hui Autonomous Region, the People’s Republic of China. Parasit Vectors 2012, 5:146. BioMed Central Full Text
• [6]Chai JJ: Echinococcosis control in China: challenges and research needs. Chin J Parqasitol Parasitic Dis 2009, 27:379-383.
• [7]Davis A, Dixon H, Pawlowski ZS: Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 1989, 67:503-508.
• [8]Davis A, Pawlowski ZS, Dixon H: Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. Bull World Health Organ 1986, 64:383-388.
• [9]Eckert J, Gemmell MA, Meslin FX, Pawlowski ZS: WHO/OIE Manual on echinococcosis in humans and animals: a public health problem of global concern.Paris: Office International des Epizooties 2001, 21–72.
• [10]Li T, Ito A, Pengcuo R, Sako Y, Chen X, Qiu D, Xiao N, Craig PS: Post-treatment follow-up study of abdominal cystic echinococcosis in tibetan communities of northwest Sichuan Province, China. PLoS Negl Trop Dis 2011, 5:e1364.
• [11]Yang YQ, Zhang CW, Xiao SH: Histological comparison of the effect of praziquantel, mebendazole and albendazole on Echinococcus granulosus cyst in vivo and in vitro. Endem Dis Bull 1990, 5:17-20.
• [12]Morris DL, Chinnery JB, Ubhi C: A comparison of the effects of albendazole, its sulphone metabolite, and mebendazole on the viability of protoscoleces of Echinococcus granulosus in an in vitro culture system. Trans R Soc Trop Med Hyg 1987, 81:804-806.
• [13]Eckert J, Pawlowski Z, Dar FK, Vuitton DA, Kern P, Savioli L: Medical aspects of echinococcosis. Parasitol Today 1995, 11:273-276.
• [14]Horton RJ: Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997, 64:79-93.
• [15]Vutova K, Mechkov G, Vachkov P, Petkov R, Georgiev P, Handjiev S, Ivanov A, Todorov T: Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999, 93:357-365.
• [16]Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ: The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 2004, 272:29-36.
• [17]Schantz PM, Van den Bossche H, Eckert J: Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 1982, 67:5-26.
• [18]Liu CS, Zhang HB, Jiang B, Yao JM, Tao Y, Xue J, Wen AD: Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of Echinococcus granulosus. Parasitol Res 2012, 111:1205-1211.
• [19]Lur’e AA, Shcherbakov AM: Use of mebendazole in a mixture with sunflower seed oil (pharmacokinetic research). Med Parazitol parazitarnye bolezni 1988, 5:43-46.
• [20]Shcherbakov AM, Lur’e AA: Clinical trial of the possibility of increasing the bioavailability of mebendazole using sunflower oil in echinococcosis. Meditsinskaia parazitologiia i parazitarnye bolezni 1989, 3:46-49.
• [21]Mingjie W, Shuhua X, Junjie C, Bin L, Cheng F, Weixia S, Hotez P: Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. Acta Trop 2002, 83:177-181.
• [22]Xiao SH, Yang JQ, Wang MJ, Jiao PY, Guo FH, Chai JJ, Jiao W, Hotez P: Augmented bioavailability and cysticidal activity of albendazole reformulated in soybean emulsion in mice infected with Echinococcus granulosus or Echinococcus multilocularis. Acta Trop 2002, 82:77-84.
• [23]Dzhabarova VI, Veretennikova NL, Kovrova EA: Experimental chemotherapy of echinococcosis. 13. The effect of mebendazole in combination with a vegetable oil on the larval cysts of Echinococcus multilocularis and the reaction of the infested host to long-term administration of the preparation. Meditsinskaia parazitologiia i parazitarnye bolezni 1994, 1:26-29.
• [24]Chai J, Menghebat , Jiao W, Sun D, Liang B, Shi J, Fu C, Li X, Mao YD, Wang XL, Dolikun G, Wang YC, Gao FH, Xiao SH: Clinical efficacy of albendazole emulsion in treatment of 212 cases of liver cystic hydatidosis. Chin Med J (Engl) 2002, 115:1809-1813.
• [25]Chai JJ, Menghebat , Jiao W, Sun DY, Liang B, Shi JC, Fu C, Li X, Mao YD, Wang XL, Dolikun G, Wang YC, Gao FH, Xiao SH: Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis. Parasitol Int 2004, 53:3-10.
• [26]Xiao SH, You JQ, Jiao PY, Guo HF: Studies on the effects of mebendazole, albendazole and their metabolites in an experimental therapy of mice infected with secondary cysts of Echinococcus granulosus. Endem Dis Bull 1990, 5:11-19.
• [27]Xiao SH, Yang YQ, You JQ, Shen BG, Jiao W, Chai JJ: Effects of benzimidazole compounds on mice infected with secondary cysts of Echinococcus granulosus. Chin Med J (Engl) 1994, 107:521-532.
• [28]Chiba Y, Kohri N, Iseki K, Miyazaki K: Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol. Chem Pharm Bull (Tokyo) 1991, 39:2158-2160.
• [29]Li Y, Sun DJ, MA D: The pharmacokinetics and relative bioavailability of mebendazole peppets after oral administration. Chin J Hosp Pharm 1999, 19:649-651.
• [30]Luo L, Sun DJ, Miao AD, Wang PF: Pharmacokintic study of β-CD mebendazole in rabits. Northwest Pharmaceut J 2000, 15:118-119.
• [31]Dawson M, Watson TR: The effect of dose form on the bioavailability of mebendazole in man. Br J Clin Pharmacol 1985, 19:87-90.
• [32]Daniel-Mwuambete K, Ponce-Gordo F, Torrado J, Torrado S, Cuesta-Bandera C: Effect of two formulations of benzimidazole carbamates on the viability of cysts of Echinococcus granulosus in vivo. Parasite 2003, 10:371-373.
• [33]Xue HX, Mo HM, Sun DJ: The effect of trial treatment mebendazole dazole pellet on secondary hydatid cyst. Endem Dis Bull 2000, 15:11-14.
• [34]Xiao SH, Yang YQ, Guo HF, Zhang CW, Jiao PY, You JQ, Jiao W: Effect of mebendazole, albendazole and albendazole sulfoxide on glycogen contents of Echinococcus granulosus cysts in infected mice. Acta Pharmacol Sin 1990, 11:546-549.
• [35]Luder PJ, Witassek F, Weigand K, Eckert J, Bircher J: Treatment of cystic echinococcosis (Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens. Eur J Clin Pharmacol 1985, 28:279-285.
• [36]Witassek F, Burkhardt B, Eckert J, Bircher J: Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacol 1981, 20:427-433.
• [37]Li HT, Shan JY, Shao YM, Tuergan A, Ayifuhan A, Ran B, Wen H: Clinical effect and safety of liposomal-albendazole and tablet-albendazole for the treatment of human cystic echinococcosis. Zhonghua gan zang bing za zhi 2011, 19:532-536.
• [38]Ammann RW, Eckert J: Cestodes. Echinococcus. Gastroenterol Clin North Am 1996, 25:655-689.
• [39]Venkatesan P: Albendazole. J Antimicrob Chemother 1998, 41:145-147.